Artiva Biotherapeutics, Inc. ARTV
4.07 USD +0.01 (+0.25%)
At closeNov 11, 2026, 4:01 PM EST
4.07 0.00 0.00%
After hours · Nov 11, 4:01 PM ET
4.05 Day range 4.13
2.96 52-week range 14.53
- YTD
- -5.13%
- 1 year
- +13.37%
News
benzinga.com Deal Dispatch: DoorDash Buys Instacart For $17B, Thrive Holdings Acquires ADT, SalesForce Nabs Rune Technologies Major M&A deals this week include: Blue Matter buys Cognite, RadNet acquires ONRAD, Oak Hill Capital buys Wyyerd.
benzinga.com Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation Artiva Biotherapeutics Inc. (NASDAQ:ARTV) announced it will halt further clinical development of its lead cell therapy candidate, slash roughly 94% of its workforce, and evaluate strategic…
benzinga.com Artiva Biotherapeutics Plunges Into Crisis Over Patient Deaths and Possible Liquidation Artiva Biotherapeutics ends its AlloNK program after fatal safety events, slashes 94% of its workforce, and weighs strategic liquidation.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release,…
benzinga.com Crude Oil Moves Lower; Corning Earnings Top Views U.S. stocks mostly rose Tuesday: S&P 500 +0.5%, Nasdaq +1.1%, while Dow slipped. Oil fell 1.5%; Corning beat Q3 estimates.
benzinga.com Wedbush Downgrades Artiva Biotherapeutics to Neutral, Lowers Price Target to $4 Wedbush analyst David Nierengarten downgrades Artiva Biotherapeutics (NASDAQ:ARTV) from Outperform to Neutral and lowers the price target from $40 to $4.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 14.6% to $3.3 during Tuesday's pre-market session. The company's market cap stands at $14.4 million. Pomdoctor (NASDAQ:POM) stock…
benzinga.com Artiva Biotherapeutics Cancels ACR Convergence 2026 Data Presentation And November 9 Investor Webcast Following AlloNK Development Discontinuation Clinical Development Discontinuation and Patient Follow-UpUpdated clinical response data from patients receiving AlloNK in combination with rituximab continued to demonstrate deep B cell depletion…
benzinga.com Artiva Biotherapeutics To Reduce Workforce By ~94% Following Discontinuation Of AlloNK Development Strategic Alternatives and Corporate RestructuringArtiva’s Board of Directors is evaluating internal options and potential strategic alternatives intended to maximize stockholder value. Leerink…
benzinga.com Artiva Biotherapeutics Halts Further Development Of AlloNK Following Fatal Safety Events And FDA-Requested Enrollment Pause Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial Updated deep B cell depletion and clinical response data is consistent with previously reported…
globenewswire.com Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK® Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial Updated deep B cell depletion and clinical response data is consistent with previously reported…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics…
globenewswire.com Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026 Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with…
benzinga.com Cantor Fitzgerald Reiterates Overweight on Artiva Biotherapeutics, Maintains $40 Price Target Cantor Fitzgerald analyst Josh Schimmer reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and maintains $40 price target.- benzinga.com Artiva Biotherapeutics Presents Updated Clinical, Safety And Translational Data For AlloNK In Combination With Rituximab At 17th ISSjD 2026 In Paris Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients…
globenewswire.com Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren's Disease (ISSjD 2026) Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren's Disease (ISSjD 2026)
globenewswire.com Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren's Disease SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible…
globenewswire.com Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible…
globenewswire.com Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026 Updated clinical data expected in the second half of 2026 from at least 20 patients with refractory rheumatoid arthritis (RA) treated with AlloNK and rituximab in the ongoing company-sponsored Phase…
benzinga.com Alpha Buying: 4 Biotech Stocks a Healthcare Specialist Is Buying Biotechnology investing is a strange corner of the market. A company can own a drug that may eventually produce billions of dollars in sales and still find itself scrambling to raise enough cash to…
globenewswire.com Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible…
defenseworld.net 2,353,304 Shares in Artiva Biotherapeutics, Inc. $ARTV Acquired by 5AM Venture Management LLC 5AM Venture Management LLC acquired a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) in the second quarter, according to the company in its most recent 13F filing with the SEC.…
defenseworld.net Contrasting Artiva Biotherapeutics (NASDAQ:ARTV) & ProQR Therapeutics (NASDAQ:PRQR) ProQR Therapeutics (NASDAQ: PRQR - Get Free Report) and Artiva Biotherapeutics (NASDAQ: ARTV - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will…
globenewswire.com Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®'s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive…
globenewswire.com Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell…
zacks.com Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year? Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared to their sector so far this year.
globenewswire.com Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell…
benzinga.com Why Cracker Barrel Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket Cracker Barrel (CBRL) stock rises in pre-market trading after reporting better-than-expected Q3 results and raising FY26 sales guidance.
benzinga.com Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $41 Price Target Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $41 price target.- benzinga.com Artiva Biotherapeutics Announces Clinical, Safety And Translational Data For AlloNK, Its Allogeneic, Non-Genetically Modified Natural Killer Cell Therapy Candidate Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic
globenewswire.com Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today Multiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic…
prnewswire.com The $13 Million Company Teaching the Immune System to Hunt Cancer /PRNewswire/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ: GTBP)
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
globenewswire.com Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell…- benzinga.com Artiva Biotherapeutics Announces Data Presentations On Allogenic NK Cell Therapy June 3-6 Abstracts:LB0003Oral PresentationAB-101, an Outpatient-Administered Allogeneic NK Cell Therapy Combined with Rituximab, Generates Robust Clinical Efficacy Responses Comparable with Autologous CAR T…
globenewswire.com Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible…
globenewswire.com Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple…- benzinga.com Needham Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $41 Needham analyst Gil Blum maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $18 to $41.
benzinga.com Cantor Fitzgerald Maintains Overweight on Artiva Biotherapeutics, Raises Price Target to $40 Cantor Fitzgerald analyst Josh Schimmer maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Overweight and raises the price target from $10 to $40.
benzinga.com Wedbush Maintains Outperform on Artiva Biotherapeutics, Raises Price Target to $40 Wedbush analyst Martin Fan maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Outperform and raises the price target from $23 to $40.
seekingalpha.com Artiva Biotherapeutics: 'Buy' On AlloNK POC And FDA Phase 3 Alignment For Refractory RA Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3 trial of AlloNK plus rituximab in refractory RA. Company's AlloNK plus rituximab demonstrated…- benzinga.com HC Wainwright & Co. Maintains Buy on Artiva Biotherapeutics, Raises Price Target to $35 HC Wainwright & Co. analyst Emily Bodnar maintains Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and raises the price target from $15 to $35.
benzinga.com Artiva Biotherapeutics Stock Slides Despite Positive Trial Data Artiva Biotherapeutics shares fall after Phase 2a rheumatoid arthritis data and a $300 million private placement announcement.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Sonoco Products Posts Downbeat Q1 Results, Joins Target Hospitality, Calix And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session Dow futures up 250 points. Sonoco Products Co (SON) shares down 5.7% in pre-market after reporting lower-than-expected earnings and sales.- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session